Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.23 (market cap $17.89B), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.3× iShares iBoxx $ High Yield Corporate Bond ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 60 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| HYG | REGN | |
|---|---|---|
Market Cap | $17.89B | $76.14B |
Volume | 44,866,592 | 500,239 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $852.03 |
52-Week Low | $76.90 | $557.73 |
Typical Hold Time | 60 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.14, down 0.05% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF maintains consistent dividend distributions with recent payouts ranging from $0.38 to $0.44. Market sentiment is heavily influenced by the broader bond selloff as Treasury yields reach multi-decade highs, creating headwinds for high-yield corporate bonds.
Current market conditions present challenges for HYG as rising interest rates pressure high-yield bond valuations. The ETF's performance remains tied to Federal Reserve policy and corporate credit conditions, with upside potential limited until bond market volatility subsides. Key risks include further rate hikes and economic slowdown impacting junk bond issuers.
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
